| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6189791 | Brachytherapy | 2013 | 8 Pages |
Abstract
HDR-ISBT boost after EBRT offers excellent long-term local control in patients with Bartholin's gland carcinoma. HDR-ISBT should be considered for positive surgical margins or residual tumor after surgery and for locally advanced malignancies treated by primary chemoradiotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Isabelle Thibault, Marie-Claude Lavallée, Sylviane Aubin, Suneil Jain, Nathalie Laflamme, Ãric Vigneault,